Stocksigma LogoStocksigma Logo

Cipla Subsidiary InvaGen Receives NAI Classification from USFDA for New York Facility

Cipla announced that the USFDA has classified the inspection of its wholly owned subsidiary InvaGen Pharmaceuticals Inc.'s manufacturing facility in

Cipla Subsidiary InvaGen Receives NAI Classification from USFDA for New York Facility

Cipla Ltd 路 Others (Uncategorized) 路 18 Nov 2026, 4:48 am

Cipla Subsidiary InvaGen Receives NAI Classification from USFDA for New York Facility Cipla announced that the USFDA has classified the inspection of its wholly owned subsidiary InvaGen Pharmaceuticals Inc.'s manufacturing facility in Hauppauge, Long Island, New York, as No Action Indicated (NAI). The inspection was conducted between 19th Oct'26 and 22nd Oct'26, with the USFDA communicating the NAI classification on 17th Nov'26.

Original exchange filing (PDF)

More announcements from Cipla Ltd

All Cipla Ltd announcements